Duality Biotherapeutics (映恩生物) Pre-IPO: A Closer Look at Its Core Products
China's Duality Biotherapeutics aims to raise $250m through a Hong Kong listing, with a revised prospectus. In this insight, we took a closer look...
727 Views
Pre-IPO Duality Biotherapeutics (PHIP Updates) - Some Points Worth the Attention
DB-1303 face challenges in commercialization.The priority for DB-1311 is to verify the druggability. Duality’s pre-IPO valuation isn't...
595 Views
Duality Biotherapeutics (映恩生物) Pre-IPO: PHIP Updates Show Slight Improvements
China's Duality Biotherapeutics aims to raise $300m through a Hong Kong listing. We looked at the changes between previous filing and the PHIP...
595 Views
Pre-IPO Duality Biotherapeutics - Has the Potential to Surpass RemeGen
Founder Zhu Zhongyuan's role in biotech landscape helped Duality secure a high starting point, but slower R&D progress is a concern.Potential for...
691 Views
ECM Weekly (16th Sep 2024) - Midea, Bajaj Housing, 99 Speed, P N Gadgil, Hozon, Trial, NextDC, Via
Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
617 Views